2020
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
Abraham H, Xia Y, Mukherjee B, Merajver S. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Research And Treatment 2020, 185: 229-238. PMID: 33033965, DOI: 10.1007/s10549-020-05938-2.Peer-Reviewed Original ResearchConceptsSurvival timeBlack patientsBreast cancerWhite patientsSurvival rateIncidence rateIncidence of IBCInflammatory breast cancerPurposeInflammatory breast cancerResultsThe overall incidenceAge-adjusted incidence ratesMean survival timeRelative survival ratesIBC patientsT stageAggressive variantSkin progressionNo significant differenceDisease criteriaSurvival disparitiesPatientsSignificant differenceSurvivalConfidence intervalsMonthsMenopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regression
2018
Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram M, Estes J, Griggs J, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer 2018, 18: 258. PMID: 29510667, PMCID: PMC5840834, DOI: 10.1186/s12885-018-4166-3.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerFirst-line therapyProstate cancerSystemic treatmentFirst-lineSystemic treatment of advanced prostate cancerTreatment of metastatic castration-resistant prostate cancerTreatment of advanced prostate cancerResultsOur final analysisAdvanced prostate cancerFirst line therapyFood and Drug AdministrationNational insurance providerLine therapySequence of treatmentTreatment patternsDisease courseStudy cohortPrescription ratesPrescribed drugsDrug AdministrationIncreased survivalCancerTherapy